Invitation to COVID-19 Study by Octapharma

7/14/2020

Octagam 10%

As part of our commitment to Helping Healthcare Care®, we extend Octapharma's invitation to participate in an interventional clinical trial for Octagam 10% therapy in COVID-19 patients with severe disease progression.1

Sponsored by Octapharma, this is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease.

Learn more about the study at COVID19.octapharmausa.com/covid

Join the clinical trial for patients 18 years of age or older at covid19.octapharmausa.com/covid/clinical-investigator-recruitment.html

1.  Octagam 10% therapy in COVID-19 patients with severe disease progression, retrieved from https://clinicaltrials.gov/ct2/show/NCT04400058?term=gam10-10&draw=2&rank=1

       
Octapharma     For questions, please contact:
Snehal Udavat, Clinical Operations
Email: snehal.udavat@octapharma.com
Phone: (201) 604-1124